Perspectives on Cancer Genome Profiling

PGDx BLOG

PGDx Takes on ASCO

Every year, 40,000 oncology professionals gather in Chicago for ASCO (American Society of Clinical Oncology), the largest cancer conference in the world. Presenters at this meeting reveal new findings on promising therapies, introduce intriguing theories on anything from cancer biology to clinical practice, and inevitably spark controversial discussions from around the field…

MSI 2.0

On May 23, the FDA announced it has granted accelerated approval of Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for use as a pan-cancer therapeutic in solid tumors with detectable levels of the microsatellite instability-high (MSI-H) biomarker. This is the first time the FDA has approved a cancer treatment targeting a specific genetic feature…

MSI Analysis Makes PlasmaSELECT 64 Even More Powerful.

PGDx is excited to announce we’ve expanded PlasmaSELECT 64 to add microsatellite instability analyses. Called PlasmaSELECT 64 + MSI, it is now the only pan-cancer assay for tumor profiling that can also evaluate MSI status in plasma.PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer…

AACR 2017 Quick Glance

From April 1–5, 21,000 scientists gathered in Washington, D.C., for AACR, the largest cancer research conference in the world. Among hundreds of talks and thousands of posters, the most high-profile speaker was former Vice President Joe Biden, who spoke about the powerful Cancer Moonshot Initiative, noting both its recent progress and the…

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatellite instability (MSI). Resulting from deficient mismatch-repair (MMR), MSI is a clinically relevant condition characterized by the progressive shortening of mononucleotide genomic tracts. With recent advances in precision medicine, our ability to detect MMR deficiency in patients has taken…

12